A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis
| Status: | Completed |
|---|---|
| Conditions: | Nephrology |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any - 50 |
| Updated: | 11/23/2013 |
| Start Date: | July 2013 |
| End Date: | August 2014 |
| Contact: | Christopher S. James, M.D. |
| Email: | chris.james@retrophin.com |
| Phone: | 646-495-5077 |
This is a study to investigate RE-021 in patients with focal segmental glomerulosclerosis
(FSGS)
Inclusion Criteria:
Biopsy-proven primary FSGS (Primary FSGS confirmed by renal biopsy report OR documentation
of a genetic mutation in a podocyte protein associated with the disease)
We found this trial at
1
site
Click here to add this to my saved trials
